Vitamin D-ghrelin conjugates
First Claim
Patent Images
1. A carrier-drug conjugate, comprising a targeting group that is vitamin D that is not hydroxylated at the Carbon 1 position stably linked to a therapeutic peptide having Ghrelin activity comprising an amino acid sequence with at least a 90% sequence identity to SEQ ID NO:
- 5.
4 Assignments
0 Petitions
Reexamination
Accused Products
Abstract
The invention provides carriers that enhance the absorption, half-life or bioavailability of Ghrelin peptides. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.
113 Citations
25 Claims
- 1. A carrier-drug conjugate, comprising a targeting group that is vitamin D that is not hydroxylated at the Carbon 1 position stably linked to a therapeutic peptide having Ghrelin activity comprising an amino acid sequence with at least a 90% sequence identity to SEQ ID NO:
-
11. A pharmaceutical composition, comprising:
-
(a) a therapeutic peptide having Ghrelin activity comprising an amino acid sequence with at least a 90% sequence identity to SEQ ID NO;
5,(b) a stably attached scaffold, (c) a targeting group that is vitamin D that is not hydroxylated at the Carbon 1 position, wherein after administration to a first subject, said therapeutic peptide has a half life measured by an Enzyme Linked Immunosorbant Assay (ELISA) analysis of blood samples taken at a plurality of time points that is greater than a half life of said therapeutic peptide administered to a second subject without said attached scaffold and targeting group as measured by said ELISA analysis of blood samples taken at said plurality of time points. - View Dependent Claims (12, 13)
-
- 14. A carrier-drug conjugate, comprising a stably linked targeting group that is vitamin D that binds a vitamin D binding protein with a higher affinity than said carrier-drug conjugate binds to a vitamin D receptor, wherein said carrier-drug conjugate comprises a therapeutic peptide having Ghrelin activity further comprising an amino acid sequence with at least a 90% sequence identity to SEQ ID NO:
-
23. A pharmaceutical composition, comprising:
-
(a) a therapeutic peptide having Ghrelin activity comprising an amino acid sequence with at least a 90% sequence identity to SEQ ID NO;
5,(b) a stably attached scaffold, (c) a targeting group that is Vitamin D, wherein after administration to a first subject, said therapeutic peptide has a half life measured by an ELISA analysis of blood samples taken at a plurality of time points that is greater than a half life of said therapeutic peptide administered to a second subject without said attached scaffold and targeting group as measured by said ELISA analysis of blood samples taken at said plurality of time points. - View Dependent Claims (24, 25)
-
Specification